Common Terminology Criteria for Adverse Events (CTCAE)

Therapy and Dosimetry (General)

Beylergil V., et al. (2013) A Historical Perspective on the Use of Radionuclides for Therapy. In: Baum R. (eds) Therapeutic Nuclear Medicine. Medical Radiology. Springer, Berlin, Heidelberg.

Gomes Marin JF, et al. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology. Radiographics. 2020 Oct;40(6):1715-1740.

Iodine-131 Thyroid Cancer

Haugen BR, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133.

Francis GL, et al; American Thyroid Association Guidelines Task Force. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015 Jul;25(7):716-59.

Iodine-131 Hyperthyroidism

Ross DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-1421.

Silberstein EB, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012 Oct;53(10):1633-51.

Iodine-131 iobenguane (Azedra)

Lutetium-177 dotatate (Lutathera)

Burkett BJ, et al. How We Do It: A Multidisciplinary Approach to 177Lu DOTATATE Peptide Receptor Radionuclide Therapy. Radiology. 2021 Feb;298(2):261-274.

Bellizzi AM. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am. 2020 Apr;29(2):185-208.

Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med. 2018;59(1):66-74. doi:10.2967/jnumed.117.202275 

Pencharz D, Gnanasegaran G, Navalkissoor S. Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy. Br J Radiol. 2018;91(1091):20180108. doi:10.1259/bjr.20180108

Lutetium-177 PSMA (Pluvicto)

Highlights of Prescribing Information (Package Insert)

Sartor O, Herrmann K. Prostate Cancer Treatment: 177Lu-PSMA-617 Considerations, Concepts, and Limitations. J Nucl Med. 2022 Jun;63(6):823-829.

Vorster M, Sathekge MM. Theranostics in Metastatic Castrate Resistant Prostate Cancer. In: Bott SRJ, Ng KL, eds. Prostate Cancer. Exon Publications; 2021. Accessed February 1, 2023. ISBN: 978-0-6450017-5-4.

Radium-223 chloride (Xofigo)

Yttrium-90 microspheres (SirTex and Theraspheres)

Lee EJ, Chung HW, Jo JH, So Y. Radioembolization for the Treatment of Primary and Metastatic Liver Cancers. Nucl Med Mol Imaging. 2019 Dec;53(6):367-373. doi: 10.1007/s13139-019-00615-9.